Comparing treatments for babies with opioid withdrawal
Part of Mental health, Pain clinical trials.
This study looks at different medicine approaches to treat newborns with opioid withdrawal (NOWS). It compares how well babies do with standard care and may help find the best way to manage symptoms and support recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby must be born at 36 weeks or later (full-term or close to it).
- Your baby must have had exposure to opioids before birth (from mom’s use, a positive test, or medical records).
- Your baby must be showing moderate to severe withdrawal symptoms (like a high Finnegan score or needs help with eating, sleeping, or comforting).
- Your baby cannot have major birth defects, brain injuries, or other serious newborn conditions.
- Your baby cannot be on breathing support (like oxygen or a breathing machine) at 48 hours old.
- Your baby must be treated at a hospital that is part of this study, and all criteria must have been met on or after March 25, 2024.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny genetic signals (microRNA) in newborn samples to identify neonatal opioid withdrawal syndrome. It may help doctors recognize withdrawal sooner, so babies can get the right care faster.
This study looks at how opioid exposure during pregnancy affects blood flow and brain function in newborns. Researchers will compare babies exposed to opioids in the womb with babies who were not exposed, to better understand how prenatal opioid exposure affects the developing brain.
This program helps participating hospitals improve care for newborns who may go through opioid withdrawal (also called neonatal abstinence syndrome). It mainly aims to make mother-baby support and treatment plans work better after delivery.
This study is collecting information from two groups of newborns: those with Neonatal Abstinence Syndrome (NAS, caused by drug exposure before birth) and healthy newborns. The goal is to see if an automated system makes it easier to gather data without extra tests or procedures.
This study aims to improve care for mothers with opioid use disorder and their babies with neonatal abstinence syndrome. Researchers will interview healthcare providers and mothers to develop better support programs.
This study looks at how the placenta and baby's development may be affected when a mother takes buprenorphine or methadone for opioid use disorder during pregnancy. It aims to find better ways to monitor health and improve outcomes for both mothers and babies.
Hear when a new Neonatal Opioid Withdrawal Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.